Contents

Contents

• Perspective

  • Rituximab’s New Therapeutic Target: The Podocyte Actin Cytoskeleton

    By Andrew C. Chan

    Science Translational Medicine01 Jun 2011 : 85ps21 Full AccessRestricted Access

    A well-characterized monoclonal antibody drug imparts therapeutic benefit in kidney disease through an off-target–mediated mechanism.

    • Abstract
    • Full Text
    • PDF

• Research Articles

  • Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis

    By Alessia Fornoni, Junichiro Sageshima, Changli Wei, Sandra Merscher-Gomez, Robier Aguillon-Prada, Alexandra N. Jauregui, Jing Li, Adela Mattiazzi, Gaetano Ciancio, Linda Chen, Gaston Zilleruelo, Carolyn Abitbol, Jayanthi Chandar, Wacheree Seeherunvong, Camillo Ricordi, Masami Ikehata, Maria Pia Rastaldi, Jochen Reiser, George W. Burke III

    Science Translational Medicine01 Jun 2011 : 85ra46 Full AccessRestricted Access

    Rituximab treatment in high-risk patients with focal segmental glomerulosclerosis directly affects podocyte function and is linked to reduced incidence of recurrent proteinuria after kidney transplantation.

    • Editor's Summary
    • Abstract
    • Full Text
    • PDF

  • A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma

    By Natsuko Suwaki, Elsa Vanhecke, Katelyn M. Atkins, Manuela Graf, Katherine Swabey, Paul Huang, Peter Schraml, Holger Moch, Amy Mulick Cassidy, Daniel Brewer, Bissan Al-Lazikani, Paul Workman, Johann De-Bono, Stan B. Kaye, James Larkin, Martin. E. Gore, Charles L. Sawyers, Peter Nelson, Tomasz M. Beer, Hao Geng, Lina Gao, David Z. Qian, Joshi J. Alumkal, Gary Thomas, George V. Thomas

    Science Translational Medicine01 Jun 2011 : 85ra47 Full AccessRestricted Access

    Signaling through the VHL-PTP1B-Src pathway in renal cell carcinomas may determine sensitivity to Src inhibitors and provide a basis for treatment planning.

    • Editor's Summary
    • Abstract
    • Full Text
    • PDF

  • MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

    By Surender Khurana, Nitin Verma, Jonathan W. Yewdell, Anne Katrin Hilbert, Flora Castellino, Maria Lattanzi, Giuseppe Del Giudice, Rino Rappuoli, Hana Golding

    Science Translational Medicine01 Jun 2011 : 85ra48 Full AccessRestricted Access

    Adjuvant use improves the quality and quantity of the immune response to pandemic influenza vaccines.

    • Editor's Summary
    • Abstract
    • Full Text
    • PDF

• Editors' Choice

  • DPP4 Joins Weight Watchers

    By Mickie H. Cheng

    Science Translational Medicine01 Jun 2011 : 85ec80 Full AccessRestricted Access

    In patients with metabolic syndrome, human visceral fat secretes an adipokine DPP4 that impairs insulin signaling in muscle, potentially contributing to insulin resistance.

    • Full Text

  • Old Dogs and New Tricks

    By David S. Hong

    Science Translational Medicine01 Jun 2011 : 85ec81 Full AccessRestricted Access

    A combination of standard cytotoxic chemotherapies used for other cancers extends overall survival for pancreatic cancer patients.

    • Full Text

  • Molecular Sleuthing: Linking Leprosy and Armadillos

    By Melissa Nyendak

    Science Translational Medicine01 Jun 2011 : 85ec82 Full AccessRestricted Access

    Investigators use molecular epidemiology to link leprosy with armadillo exposure, suggesting a new zoonotic mode of transmission.

    • Full Text

  • The Changing Brain

    By Wei Wang

    Science Translational Medicine01 Jun 2011 : 85ec83 Full AccessRestricted Access

    Spinal cord injury can potentially lead to adaptive changes in the sensory and motor cortical areas of the brain.

    • Full Text